Drug profile

The FDA adverse-event record for Chlorhexidine Gluconate + Climbazole + Phytosphingosine Salicyloyl

209 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Chlorhexidine Gluconate + Climbazole + Phytosphingosine Salicyloyl. See the species affected, top reactions, and outcomes below.

209
adverse-event reports
1.4%
death-coded share
Dog
most-reported species
59
Application site erythema - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
209
Total Reports
3
Deaths Reported
1.4%
Death Rate

Active Ingredients

Chlorhexidine GluconateClimbazolePhytosphingosine Salicyloyl

Administration Routes

TopicalOphthalmicOralUnknown

Species Affected

Dog 174
Cat 23
Human 12

Most Affected Breeds

Crossbred Canine/dog 29
Mixed (Dog) 16
Unknown 13
Shih Tzu 12
Cat (unknown) 10
Bulldog 8
Retriever - Golden 8
Retriever - Labrador 7
Terrier - Yorkshire 7
Dog (unknown) 7

Most Reported Reactions

Application site erythema 59
Application site pruritus 24
Application site irritation 14
Application site reddening 13
Application site hair coat discolouration 7
Vomiting 7
Application site dermatitis 7
Application site pain 6
Application site inflammation 6
Pruritus 6
Lethargy (see also Central nervous system depression in 'Neurological') 6
Hives (see also 'Skin') 5

Outcome Breakdown

Recovered/Normal
103 (49.3%)
Ongoing
80 (38.3%)
Outcome Unknown
22 (10.5%)
Died
2 (1.0%)
Euthanized
1 (0.5%)
Recovered with Sequela
1 (0.5%)

Chlorhexidine Gluconate + Climbazole + Phytosphingosine Salicyloyl Adverse Event Insights

209 reports name Chlorhexidine Gluconate + Climbazole + Phytosphingosine Salicyloyl; 3 recorded a death outcome (1.4% of reported events, not a population-level mortality rate). Active ingredients: Chlorhexidine Gluconate, Climbazole, Phytosphingosine Salicyloyl. Administration routes: Topical, Ophthalmic, Oral, Unknown.

By species: Dog (174 reports), Cat (23 reports), Human (12 reports). By breed: Crossbred Canine/dog (29), Mixed (Dog) (16), Unknown (13).

Leading clinical signs: Application site erythema (59), Application site pruritus (24), Application site irritation (14), Application site reddening (13). Outcome, 209 coded reports: Recovered/Normal leads at 49.3%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.